3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals
Status:
Active, not recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
The proposed study is a phase 1, open label, single arm study to evaluate the safety,
pharmacokinetics and antiviral activity of single intravenous infusions of 3BNC117-LS and
10-1074-LS, each monoclonal antibody (mAb) dosed at 30 mg/kg in viremic human
immunodeficiency virus (HIV)-infected individuals.
Phase:
Phase 1
Details
Lead Sponsor:
Rockefeller University
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID) Perelman School of Medicine University of Pennsylvania Weill Medical College of Cornell University